Literature DB >> 1816226

Sickle cell disease in India.

B C Kar1.   

Abstract

A screening programme involving 9,822 hospitalised patients revealed the frequency of individuals with S gene to be 11.1 per cent. A population survey of 1,000 randomised subjects from amongst about 70,000 people in one block of the area showed the frequency to be 15.1%. The gene is not confined to tribal peoples, but is prevalent throughout the society, being more frequent in scheduled castes and some caste Hindus. With the available Indian data a sickle cell belt can be mapped out in the country. Analysis of clinical data on the first 700 cases of sickle cell disease seen in the Sickle Cell Research Centre (ICMR) at Burla shows patients of all ages, even beyond 40 years, though many patients tend to die by 20 years of age. Genetically, while most patients are SS and 8.1% are S-beta thalassaemia, cases of SD disease and SE disease were also encountered. A frequency of 0.32% of alpha thalassaemia gene was noted in SS patients against 0.28% in sickle cell trait and 0.12% in AA controls. The disease was found to manifest as early as 3 months or may remain asymptomatic till adult life. Though generally running a milder course, moderate to severe anaemia, vaso-occlusive attacks (86.5-89.36%), splenic sequestration (8.43%-12.76%), crippling avascular bone necrosis (5.7%-35.08%), osteomyelitis (5/700), and epistaxis (28.92%-35.08%) remain a few clinical events deserving competent and urgent medical management.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1816226

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  16 in total

1.  The Chhattisgarh state screening programme for the sickle cell gene: a cost-effective approach to a public health problem.

Authors:  P K Patra; P K Khodiar; I R Hambleton; G R Serjeant
Journal:  J Community Genet       Date:  2015-03-31

2.  Clinical profile of sickle cell disease in Orissa.

Authors:  B C Kar; S Devi
Journal:  Indian J Pediatr       Date:  1997 Jan-Feb       Impact factor: 1.967

Review 3.  Renal Medullary Carcinoma: Establishing Standards in Practice.

Authors:  Kathryn E Beckermann; Deva Sharma; Shruti Chaturvedi; Pavlos Msaouel; Miguel R Abboud; Yves Allory; Franck Bourdeaut; Julien Calderaro; Aguirre A de Cubas; Vimal K Derebail; Andrew L Hong; Rakhi P Naik; Gabriel G Malouf; Elizabeth A Mullen; Victor E Reuter; Charles W M Roberts; Cheryl L Walker; Christopher G Wood; Michael R DeBaun; Hendrik Van Poppel; Nizar M Tannir; W Kimryn Rathmell
Journal:  J Oncol Pract       Date:  2017-07       Impact factor: 3.840

4.  Screening for the sickle cell gene in Chhattisgarh state, India: an approach to a major public health problem.

Authors:  Pradeep K Patra; Virander S Chauhan; Prafulla K Khodiar; Abdul R Dalla; Graham R Serjeant
Journal:  J Community Genet       Date:  2011-06-15

5.  The screening and morbidity pattern of sickle cell anemia in chhattisgarh.

Authors:  Sumanta Panigrahi; P K Patra; P K Khodiar
Journal:  Indian J Hematol Blood Transfus       Date:  2014-06-13       Impact factor: 0.900

6.  Hemoglobinopathies in South Gujarat population and incidence of anemia in them.

Authors:  Ankur G Patel; Avani P Shah; Smita M Sorathiya; Snehalata C Gupte
Journal:  Indian J Hum Genet       Date:  2012-09

7.  Search for antisickling agents from plants.

Authors:  Bisnu Prasad Dash; Y Archana; Nibarana Satapathy; Soumendra Kumar Naik
Journal:  Pharmacogn Rev       Date:  2013-01

8.  Prevalence of deletional alpha thalassemia and sickle gene in a tribal dominated malaria endemic area of eastern India.

Authors:  Prasanta Purohit; Snehadhini Dehury; Siris Patel; Dilip Kumar Patel
Journal:  ISRN Hematol       Date:  2014-03-11

9.  Sickle cell disease in India: A perspective.

Authors:  Graham R Serjeant; Kanjaksha Ghosh; Jyotish Patel
Journal:  Indian J Med Res       Date:  2016-01       Impact factor: 2.375

Review 10.  Evolving locally appropriate models of care for indian sickle cell disease.

Authors:  Graham R Serjeant
Journal:  Indian J Med Res       Date:  2016-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.